The effectiveness and safety of the drug Mexol Forte 250 in the framework of consecutive therapy in patients with chronic brain ischemia

Author:
E.I. CHUKANOVA, A.S. CHUKANOVA

Department of Neurology, Neurosurgery and Medical Genetics of Faculty of Faculty of Faculty of FSBEI in "RNIMU named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2019, Vol. 119, No. 9

Abstract:
Objective of the study. To study the efficacy and safety of therapy with the medicinal product (MP) Mexidol used intravenously by drip (500 mg once a day) in the form of infusions for 14 days, followed by oral administration of the medicinal product Mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days in patients with chronic cerebral ischemia associated with arterial hypertension and atherosclerosis. Material and methods. The open observational program included 60 patients with an established diagnosis of chronic cerebral ischemia, confirmed by neuroimaging methods. Results and conclusion. The results of the study demonstrated high efficacy and safety of sequential therapy (injections and then administration of the tablet form of the medicinal product Mexidol FORTE 250). During the treatment, an improvement in emotional and cognitive status, a decrease in motor disorders, as well as the severity of subjective manifestations were noted. High patient compliance to the therapy was demonstrated. Key words:chronic cerebral ischemia, arterial hypertension, atherosclerosis, ethylmethylhydroxypyridine succinate, mexidol, cognitive impairment.